BioCentury | Jan 25, 2020
Product Development

Radiotherapy blasts forward

High-wattage takeouts and commercial launches have revived interest in radiopharmaceuticals for cancer. The challenge for the new wave of candidates is to achieve enough differentiation to justify the logistical hurdles of manufacturing and delivering products...
BioCentury | Sep 2, 2013
Company News

GlaxoSmithKline sales and marketing update

GlaxoSmithKline will discontinue the manufacture and sale of cancer drug Bexxar tositumomab, effective Feb. 20, 2014. The company said it decided to discontinue the product because "use of Bexxar has been extremely limited and is...
BioCentury | Feb 14, 2011

Decelerated approval

After years of hints, complaints and informal discussion, FDA has explicitly asked its Oncologic Drugs Advisory Committee - and ODAC has agreed - to raise the hurdle cancer drugs will have to clear in order to receive...
BioCentury | Jan 7, 2011
Politics & Policy

ODAC to discuss accelerated approval requirements

FDA's Oncologic Drugs Advisory Committee will meet on Feb. 8 to discuss ways to improve postmarketing trials required to confirm the benefit of drugs that received accelerated approval. The committee will review the status of...
BioCentury | Mar 25, 2010
Cover Story

A B cell burden in prostate cancer

Although castration therapies such as androgen ablation are standard prostate cancer treatments, many patients develop resistance in 12-18 months. 1 Now, researchers from the University of California, San Diego and Scripps Florida have found that...
BioCentury | Jan 5, 2009
Company News

Genmab, GlaxoSmithKline deal

Genmab declined to exercise its option to co-promote Arzerra ofatumumab, Bexar tositumomab and Arranon / Atriance nelarabine in exchange for a $4.5 million payment from GlaxoSmithKline that will be triggered by FDA's acceptance of the...
BioCentury | Sep 24, 2007

Asset accumulation

Asset accumulation Product Target Indication Status Atriance nelarabine (A) DNA synthesis Lymphoblastic leukemias Mkt (Nordic rights) Bexxar tositumomab (A) CD20 Non-Hodgkin's lymphoma (NHL) Mkt (U.S. rights) HuMax-CD4 zanolimumab CD4 Cutaneous T cell lymphoma (CTCL) Ph...
BioCentury | Sep 24, 2007

Genmab's commercial stockpile

Since the start of the year, Genmab A/S has been mulling whether to exercise an option under a 2006 deal with GlaxoSmithKline plc to co-promote cancer antibody HuMax-CD20 ofatumumab. Recent developments in two other alliances...
BioCentury | Aug 13, 2007
Tools & Techniques

Dynamic dimerization

InNexus Biotechnology Inc. chose a well-validated target, CD20 , to show that its second generation, conjugated monoclonal antibodies are more potent than first generation, unconjugated MAbs. Last week, InNexus (TSX-V:IXS; IXSBF, Vancouver, B.C.) disclosed in vitro...
BioCentury | Jan 1, 2007
Company News

Genmab, GlaxoSmithKline deal

GSK received global exclusive rights to co-develop and commercialize GEN's ofatumumab ( HuMax-CD20 ). GSK will pay a DKK582 million ($102 million) license fee and will invest DKK2 billion ($357 million) in GEN through the purchase...
Items per page:
1 - 10 of 232